載入...
Final Report on Clinical Outcomes and Tumor Recurrence Patterns of a Pilot Study Assessing Efficacy of Belinostat (PXD-101) with Chemoradiation for Newly Diagnosed Glioblastoma
Glioblastoma (GBM) is highly aggressive and has a poor prognosis. Belinostat is a histone deacetylase inhibitor with blood–brain barrier permeability, anti-GBM activity, and the potential to enhance chemoradiation. The purpose of this clinical trial was to assess the efficacy of combining belinostat...
Na minha lista:
Main Authors: | , , , , , , , , , , , , , , |
---|---|
格式: | Artigo |
語言: | Inglês |
出版: |
MDPI AG
2022-03-01
|
叢編: | Tomography |
主題: | |
在線閱讀: | https://www.mdpi.com/2379-139X/8/2/57 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|